<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">NASH and NAFLD</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="2970" role="article" about="/commodorecompendium/nash-and-nafld" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
<tbody>
<tr>
<td style="border-bottom:1px solid black; width:100%; padding:0in 7px 0in 0in; height:12px; border-top:2px double black; border-right:none; border-left:none">
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">NASH and NAFLD – John Laurenzano</span></span></b></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:&quot;Palatino Linotype&quot;,serif"><span style="color:black">Background</span></span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Non-alcoholic fatty liver disease (NAFLD): presence of hepatic steatosis in the absence of secondary causes (e.g., EtOH)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Non-alcoholic steatohepatitis (NASH): evidence of active inflammation in conjunction with steatosis (elevated liver enzymes or evidence on bx)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Strong association with metabolic syndrome, T2DM, HTN, obesity, prior cholecystectomy</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Generally asymptomatic</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Considered to be a common cause of cryptogenic cirrhosis</span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></p>
<ul style="list-style-type:circle">
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none"> </li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">NASH manifests with elevated liver enzymes, typically 2-5x the ULN, in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis), though ALT may be higher than AST </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">NAFLD is asymptomatic and frequently found incidentally via imaging</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Can be diagnosed based on imaging alone (and frequently is)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Exclusion of alternative causes and comorbid liver conditions: HCV, HBV, EtOH</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Liver biopsy</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Generally only pursued with advanced disease and to evaluate extent of fibrosis, or to rule out competing etiologies, such as AIH</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Note: Ferritin is frequently elevated, though not to the extent of HH. Low level auto-antibodies are also frequently present</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Ultrasound is used most frequently for imaging, though MRI and CT also are acceptable; </span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">use risk scores to determine the risk of advanced fibrosis and identify those who would benefit from biopsy</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Fibrosis-4 (FIB 4) score </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">NAFLD fibrosis score </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">More accurate, non invasive fibrosis assessments can be done using elastography which can be vibration based (fibroscan) ultrasound based, or MR-based</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">MR is nearly as accurate as biopsy (quantifying fat and fibrosis)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Available at VUMC and can be ordered by anyone. Insurance will not cover if BMI &lt;35</span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management </span></span></span></span></span></p>
<ul style="list-style-type:circle">
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none"> </li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Aggressive risk factor modification and mgmt of comorbidities (HLD, HTN, T2DM)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Weight loss: Mediterranean diet&gt;Low fat diet, (dose dependent improvement)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">No specific medications are FDA approved currently </span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pioglitazone has shown benefit in pts with T2DM and NASH</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Vitamin E has shown benefit in pts w/o T2DM and proven NASH</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Ongoing studies for SGLT-2i and GLP-1ra; some promise indicated for the latter</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">While bariatric surgery is not a specific indication for NASH/NAFLD, increasing evidence demonstrates resolution of NASH and fibrosis in pts with clinically significant weight loss</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Referral to the surgical weight loss clinic should be considered in any patient who meets obesity guidelines for bariatric surgery (BMI &gt;40, or &gt;35 with metabolic comorbidities) </span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Additional Information</span></span></span></span></span></p>
<ul>
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none">
<ul>
<li style="list-style-type:none"> </li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Statins: should be used for HLD in pts with NASH, NAFLD and NASH cirrhosis</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Statin use in decompensated NASH cirrhosis is controversial, and they are less likely to derive benefit given overall poor prognosis. There is an increased risk of rhabdomyolysis in pts with acute on chronic liver failure and are considered contraindicated</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Metformin is safe and may have a <b>survival benefit</b> in patients with diabetes and cirrhosis. Discontinue only in those who have increased risk for lactic acidosis (renal impairment and significant EtOH). Sulfonylureas are generally avoided.</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">While hepatic steatosis and hepatic fibrosis are diagnoses that can be made using radiologic tools, NASH requires bx as inflammation plays a key role and cannot be determined radiographically or biochemically</span></span></span></span></span></li>
</ul>
<p> </p>
</div>
</div>
</article>
</div>
</div>